Chemotherapy and Its Effect on Liver Hypertrophy: Implications for Portal Vein Embolization and Resection

ABSTRACT

Liver resection remains the gold standard treatment for colorectal liver metastases (CRLM). The improvement of the efficacy of chemotherapy has resulted in an increase of CRLM candidates for curative resection, including a significant proposition of patients initially deemed unresectable. The safety of liver resection has increased by taking advantage of regenerative capacities of the liver with preoperative portal vein embolization (PVE) and two-stage strategies. However, chemotherapy regimens including new drugs such as oxaliplatin and irinotecan may induce pathologic changes of the nontumorous liver parenchyma that could increase the risk of liver resection, and the impact of chemotherapy on the nontumorous liver parenchyma may limit tolerance of these resections. Preoperative portal obstruction, including PVE, which aimed to hypertrophy the future remnant liver, can be adversely affected by this chemotherapy. The aim of this article is to describe the impact of chemotherapy on nontumorous liver parenchyma and to evaluate the impact of chemotherapy on the regenerative capacities of the liver, especially after PVE.

KEYWORDS

Colorectal liver metastases - chemotherapy - hepatotoxicity - portal vein obstruction

REFERENCES

• 1 Scheele J, Stang R, Altendorf-Hofmann A et al.. Resection of colorectal liver metastases.  World J Surg. 1995;  19 59-71
• 2 Douillard J Y, Cunningham D, Roth A D et al.. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.  Lancet. 2000;  355 1041-1047
• 3 De Gramont A, Figer A, Seymour M et al.. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.  J Clin Oncol. 2000;  18 2938-2947
• 4 Hurwitz H, Fehrenbacher L, Novotny W et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 2335-2342
• 5 Cunningham D, Humblet Y, Siena S et al.. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.  N Engl J Med. 2004;  351 337-345
• 6 Adam R, Delvart V, Pascal G et al.. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.  Ann Surg. 2004;  240 644-657
• 7 Leonard G D, Brenner B, Kemeny N E. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma.  J Clin Oncol. 2005;  23 2038-2048
• 8 Nordlinger B, Sorbye H, Collette B et al.. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. 2007 ASCO Annual Meeting Proceedings Part I. Journal of Clinical Oncology 2007;25(18 suppl)
• 9 Jaeck D, Oussoultzoglou E, Rosso E et al.. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases.  Ann Surg. 2004;  240 1037-1049
• 10 Kianmanesh R, Farges O, Abdalla E K et al.. Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases.  J Am Coll Surg. 2003;  197 164-170
• 11 Farges O, Belghiti J, Kianmanesh R et al.. Portal vein embolization before right hepatectomy: prospective clinical trial.  Ann Surg. 2003;  237 208-217
• 12 Adam R, Laurent A, Azoulay D et al.. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors.  Ann Surg. 2000;  232 777-785
• 13 Abdalla E K, Barnett C C, Doherty D et al.. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization.  Arch Surg. 2002;  137 675-680
• 14 Zorzi D, Laurent A, Pawlik T M et al.. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.  Br J Surg. 2007;  94 274-286
• 15 Rubbia-Brandt L, Audard V, Sartoretti P et al.. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.  Ann Oncol. 2004;  15 460-466
• 16 Fernandez F G, Ritter J, Goodwin J W et al.. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.  J Am Coll Surg. 2005;  200 845-853
• 17 Karoui M, Penna C, Amin-Hashem M et al.. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.  Ann Surg. 2006;  243 1-7
• 18 Vauthey J N, Pawlik T M, Ribero D et al.. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.  J Clin Oncol. 2006;  24 2065-2072
• 19 Beal I K, Anthony S, Papadopoulou A et al.. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy.  Br J Radiol. 2006;  79 473-478
• 20 Goere D, Farges O, Leporrier J et al.. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction.  J Gastrointest Surg. 2006;  10 365-370
• 21 Parc Y, Dugué L, Farges O, Hiramatsu K et al.. Preoperative systemic 5-fluorouracil does not increase the risk of liver resection.  Hepatogastroenterology. 2000;  47 1703-1705
• 22 Yedibela S, Elad L, Wein A et al.. Neoadjuvant chemotherapy does not increase postoperative complication rate after resection of colorectal liver metastases.  Eur J Surg Oncol. 2005;  31 141-146
• 23 Aloia T, Sebagh M, Plasse M et al.. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.  J Clin Oncol. 2006;  24 4983-4990
• 24 Sahajpal A, Vollmer C M, Dixon E et al.. Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.  J Surg Oncol. 2007;  95 22-27
• 25 Hewes J C, Dighe S, Morris R W et al.. Preoperative chemotherapy and the outcome of liver resection for colorectal metastases.  World J Surg. 2007;  31 353-364
• 26 Pawlik T M, Olino K, Gleisner A L et al.. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome.  J Gastrointest Surg. 2007;  11 860-868
• 27 D'Angelica M, Kornprat P, Gonen M et al.. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.  Ann Surg Oncol. 2007;  14 759-765
• 28 Kooby D A, Fong Y, Suriawinata A et al.. Impact of steatosis on perioperative outcome following hepatic resection.  J Gastrointest Surg. 2003;  7 1034-1044
• 29 Belghiti J, Hiramatsu K, Benoist S et al.. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection.  J Am Coll Surg. 2000;  191 38-46
• 30 Gomez D, Malik H Z, Bonney G K et al.. Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis.  Br J Surg. 2007;  94 1395-1402
• 31 Peppercorn P D, Reznek R H, Wilson P et al.. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer.  Br J Cancer. 1998;  77 2008-2011
• 32 Sorensen P, Edal A L, Madsen E L et al.. Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil.  Cancer. 1995;  75 2592-2596
• 33 Moertel C G, Fleming T R, Macdonald J S et al.. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy.  J Clin Oncol. 1993;  11 2386-2390
• 34 Jones R J, Lee K S, Beschorner W E et al.. Veno-occlusive disease of the liver following bone marrow transplantation.  Transplantation. 1987;  44 778-783
• 35 Reiss U, Cowan M, McMillan A et al.. Hepatic veno-occlusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients.  J Pediatr Hematol Oncol. 2002;  24 746-750
• 36 Takayasu K, Muramatsu Y, Shima Y et al.. Hepatic lobar atrophy following obstruction of the ipsilateral portal vein from hilar cholangiocarcinoma.  Radiology. 1986;  160 389-393
• 37 Makuuchi M, Thai B L, Takayasu K et al.. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report.  Surgery. 1990;  107 521-527
• 38 Azoulay D, Castaing D, Smail A et al.. Resection of non-resectable liver metastases from colorectal cancer after percutaneous portal vein embolization.  Ann Surg. 2000;  231 480-486
• 39 Abdalla E K, Adam R, Bilchik A J et al.. Improving resectability of hepatic colorectal metastases: expert consensus statement.  Ann Surg Oncol. 2006;  13 1271-1280
• 40 Kubota K, Makuuchi M, Kusaka K et al.. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors.  Hepatology. 1997;  26 1176-1181
• 41 Shirabe K, Shimada M, Gion T et al.. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume.  J Am Coll Surg. 1999;  188 304-309
• 42 Bouzari H, Amisano M, Zorzi D et al.. Hypertrophy of the future liver remnant volume following portal vein occlusion: portal vein embolization vs portal vein ligation.  HPB. 2006;  8(suppl 2) 27-28
• 43 Aussilhou B, Lesurtel M, Sauvanet A et al.. Right portal vein ligation is as efficient as portal vein embolization to induce hypertrophy of the left liver remnant.  J Gastrointest Surg. 2008;  12 297-303
• 44 Gruenberger T, Tamandl D, Puhalla H et al.. Bevacizumab plus XELOX as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. 2007 ASCO Annual Meeting Proceedings Part I.  J Clin Oncol. 2007;  25(suppl) 4064
• 45 Engum S A, Sidner R A, Miller G A et al.. Early use of cisplatin is safe after partial hepatectomy.  J Pediatr Surg. 1993;  28 411-417